October is ADHD Awareness Month — and in 2025, it arrives at a time when the conversation around ADHD has never been louder. From waiting lists that stretch into years, to headlines about soaring diagnoses in adults, to the rise of digital therapies, the last decade has seen a huge shift in how we talk about, study and understand the condition.
For much of the twentieth century, ADHD was thought of rather narrowly: a handful of restless boys in classrooms, a short temper with homework, and a prescription for Ritalin. But the science of the past ten years has caught up with what millions of people living with ADHD already knew: it’s far more common, more complex and longer lasting than that stereotype suggests.
The research hasn’t given us one neat answer — science rarely does — but it has brought us closer to understanding what ADHD really is, where it comes from, and what helps. Here’s what we’ve learned in the last decade.
1. ADHD is common — but who gets diagnosed still depends on where you live and who you are
Large studies now put ADHD at around 5–7% of children worldwide (Polanczyk et al, 2015), with many carrying symptoms into adulthood. Yet there’s still a striking gap between prevalence and diagnosis. In England, for instance, the NHS estimates around 2.5 million people may have ADHD, but only a fraction are recorded in GP notes (BBC News, 2024).
And then there’s gender. Girls are still far less likely to be picked up in childhood — often because they present with quieter, inattentive symptoms rather than disruptive ones. Many women don’t get a diagnosis until adulthood, sometimes after years of simply thinking they weren’t coping as well as everyone else.
2. Genes matter — but they don’t write the whole story
In 2019, the largest genetic study of ADHD to date identified 12 regions of the genome linked to increased risk (Demontis et al, Nature Genetics). The takeaway? ADHD is highly heritable, but it isn’t caused by a single “ADHD gene”. Instead, it’s shaped by hundreds — maybe thousands — of tiny genetic nudges.
What’s more, many of those same genetic signals also crop up in depression, autism, and even educational attainment. So yes, ADHD runs in families, but environment, upbringing and chance still matter enormously.
3. Brain scans show patterns, but they’re not crystal balls
Pooling thousands of scans, the ENIGMA consortium has shown that children with ADHD tend to have slightly smaller volumes in certain brain regions — particularly those involved in attention and reward (Hoogman et al, 2017, Lancet Psychiatry).
It’s fascinating evidence that ADHD has a biological footprint. But here’s the catch: those brain differences are subtle, and they overlap with other conditions. In other words, we’re nowhere near the stage where you can walk into a clinic and “see” ADHD on a scan.
4. Medication: helpful for many, not the full picture
One thing the past decade has reinforced is that medication works. Reviews of dozens of trials confirm that stimulants such as methylphenidate significantly reduce core symptoms (Cortese et al, 2018, Lancet Psychiatry). Non-stimulants like atomoxetine also help, though usually to a lesser degree.
But here’s where things get more complicated: the evidence is much thinner when it comes to long-term outcomes like school performance or overall wellbeing (Cochrane Review, 2016). Medication can be life-changing for some, but it’s rarely the whole answer.
5. New frontiers: therapy, tech and even video games
Behavioural parent training remains one of the best-established non-drug approaches, especially for younger children. But the last decade has also given us something new: digital therapeutics. In 2020, the US FDA even approved the first prescription video game for ADHD, after trials showed improvements in attention scores (Kollins et al, 2020, Lancet Digital Health).
It’s not a magic bullet — the effects are modest and we need longer-term follow-up — but it points to a future where ADHD care is broader than just pills and appointments.
6. A condition across the lifespan
Perhaps the biggest shift has been in recognising ADHD as a lifespan condition. Around two-thirds of children with ADHD continue to experience symptoms as adults (Faraone et al, 2015). In adulthood, the picture often looks different: less climbing on desks, more chronic procrastination, disorganisation, or emotional rollercoasters.
For many women especially, it’s in adulthood — sometimes after their own children are diagnosed — that the penny finally drops.
So, what have we learned?
After a decade of research, we know ADHD isn’t a childhood phase, nor a personality flaw, nor a niche diagnosis. It’s a common neurodevelopmental condition with clear genetic and biological roots, shaped by the environment, and responsive to a mix of treatments.
But the science has also laid bare the gaps: long waits for assessment, limited access to non-drug interventions, and unanswered questions about long-term outcomes.
This ADHD Awareness Month, the evidence points us towards a simple conclusion: ADHD is real, common, and treatable. The challenge now is less about proving its existence and more about making sure the millions who live with it can actually access the help they need.
